Summary
Background (ECT) is an effective local treatment for cutaneous metastasis. Treatment involves the administration of chemotherapeutic drugs followed by delivery of electrical pulses to the tumour. Objectives To investigate the effectiveness of ECT in cutaneous metastases of melanoma and to identify factors that affect (beneficially or adversely) the outcome. Methods Thirteen cancer centres in the International Network for Sharing Practices on Electrochemotherapy consecutively and prospectively uploaded data to a common database. ECT consisted of intratumoral or intravenous injection of bleomycin, followed by application of electric pulses under local or general anaesthesia. Results In total, 151 patients with metastatic melanoma were identified from the database, 114 of whom had follow-up data of 60 days or more. Eighty-four of these patients (74%) experienced an overall response (OR = complete response + partial response). Overall, 394 lesions were treated, of which 306 (78%) showed OR, with 229 showing complete response (58%). In multivariate analysis, factors positively associated with overall response were coverage of deep margins, absence of visceral metastases, presence of lymphoedema and treatment of nonirradiated areas. Factors significantly associated with complete response to ECT treatment were coverage of deep margins, previous irradiation of the treated area and tumour size (< 3 cm). One-year overall survival in this cohort of patients was 67% (95% confidence interval 57-77%), while melanoma-specific survival was 74% (95% confidence interval 64-84%). No serious adverse events were reported, and the treatment was in general very well tolerated.
Conclusions ECT is a highly effective local treatment for melanoma metastases in the skin, with no severe adverse effects noted in this study. In the presence of certain clinical factors, ECT may be considered for local tumour control as an alternative to established local treatments, or as an adjunct to systemic treatments.
What's already known about this topic?
• Electrochemotherapy (ECT) is an effective local treatment for cutaneous metastasis.
• Treatment efficacy is correlated to tumour size.
What does this study add?
• With multivariate analysis, several new factors associated with a favourable response to treatment have been identified: coverage of deep tumour margin, presence of lymphoedema, treatment of nonirradiated areas and absence of visceral metastases.
Therapy and management of metastatic melanoma are challenging. Melanoma accounts for about 18% of the total cases of cutaneous metastases. 1, 2 Patients with metastatic disease may have reduced quality of life because of pain, discharge, bleeding and malodour of the tumours. In this advanced stage of the disease, multimodal palliative treatment is required, focusing on alleviating symptoms for the patients. Established therapeutic options include surgery, immunotherapy, systemic chemotherapy, isolated limb perfusion, radiotherapy, laser ablation and radiofrequency ablation, depending on the location of metastases and the condition of the patient. 3, 4 Electrochemotherapy (ECT) is a well-established treatment option for cutaneous and subcutaneous metastases, including melanoma. 5 Originally it was used for the treatment of metastatic head and neck cancer 6 and it has since been established in the treatment of tumours of different histological types. Moreover, it has a favourable risk-to-benefit profile due to its simplicity, cost-effectiveness, safety and limited toxicity. 7 Electroporation is a physical delivery system to enhance the penetration of different types of molecules, such as drugs. 6 The use of short electrical local pulses via an electrode leads to destabilization of the cell membrane and transiently increases the permeability of the tumour cell membrane, thus enabling diffusion of the agents. This potentiates the cytotoxicity of the nonpermeant or poorly permeant anticancer drug. 6, 8 The secondary actions of ECT include a reduction of tumour blood flow and localized vascular disruption resulting in increased effectiveness of the drug. [9] [10] [11] Bleomycin and cisplatin have been identified as the most suitable and effective drugs for ECT and can be used intratumorally or intravenously. 12 The cytotoxic effect of bleomycin is potentiated approximately 8000 times, and that of cisplatin 80 times. 13 Several studies have investigated the effectiveness of ECT. 
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ECT has been recognized by a number of national health services, including the U.K. National Institute for Health and Care Excellence, as an integral part of the multidisciplinary treatment options for patients with skin metastases of nonskin origin and melanoma. 5 ECT has been reported to be highly effective in the treatment of cutaneous and subcutaneous metastases. Objective response rates range from 75% to 99%. 8, 13, 23, 31 The high response rates found consistently across studies reflect a dramatic increase of the cytotoxic effect of the cytostatic drugs, such as bleomycin, when access into the cell cytosol is facilitated by permeabilization of the plasma membrane. In order for the therapy to work efficiently it is important that a sufficient drug dose is present, and that the tumour volume is covered by the electric pulses. 21, 23 The aim of this study was to review the effectiveness of ECT in cutaneous metastases of melanoma and to identify factors that affect (beneficially or adversely) the outcome. Determination of local progression-free and overall survival was a further aim of the study. The results may be used prospectively to improve the effectiveness of ECT in metastatic melanoma. This study focused on the response of ECT to local disease in the skin, and did not compare response rates with other treatment modalities for metastatic disease.
Patients and methods

Patients
Patients were treated consecutively at 13 institutions in the InspECT network (Bristol, Copenhagen, London, Manchester, Middlesbrough, Munich, Padova, Pavia, Prescot, Rome, Turin, Warsaw, Wels). Patients gave consent, then their data were entered into the database and subsequently updated over time. Coverage of deep and lateral margins was not prespecified, but was at the treating physician's discretion, and the database offered a possibility for the physician to indicate whether or not these respective margins were completely covered and/or treated. Targeting of the deep margin was assessed either clinically by palpating subcutaneous infiltration or fixation to that depth, or by using ultrasound.
Response evaluation
Locoregional tumour response was evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST version 1.0), modified to include the response of only the treated cutaneous metastases. Complete response was defined as disappearance of the target lesion, and partial response as ≥ 30% decrease in the diameter of the target lesion. Progressive disease was defined as ≥ 20% increase in the diameter of the target lesion, and stable disease as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. A maximum of seven cutaneous metastases per patient (including the largest tumour) were registered as target lesions, as in previous studies. 2, 21 The longest diameter of the tumours was measured and recorded, and photographs were taken at the time of treatment and at subsequent follow-up visits.
Preoperative evaluation
Selection of the target nodule was performed according to the RECIST criteria (version 1.1). Pain intensity was evaluated using a numerical rating scale (NRS) for pain. NRS is a unidimensional 11-point numerical scale between 0 for 'no pain' and 10 for 'worst pain'. We used previously published cut-off values for NRS score: 0-2, mild pain; 3-5, moderate pain and 6-10, severe pain. Pain medication was registered as 'none', 'sometimes', 'controlled by nonopioids', 'controlled by opioids', 'uncontrolled' or 'unknown'. Evaluation of pain and pain medication was repeated at the follow-up visit. 32 
Statistics
Continuous variables were described by median value and interquartile range, and categorical variables by absolute number and percentage. Analyses of response for different lesions' sizes were reported on a 2 9 k contingency table and analysed with a v 2 -test for trend. The v 2 -value (and degrees of freedom) are reported together with the P-value. Several groups were compared on the basis of clinical and treatment variables: sex; age (< 70 years vs. > 70 years); time since diagnosis (< 5 years vs. > 5 years); T-stage at diagnosis (T1-T2 vs. T3-T4); localization (limbs vs. other); number of treated lesions (fewer than three vs. more than three); size of lesions (≤ 3 cm vs. > 3 cm); presence of visceral metastases; treatment of preirradiated areas; presence of lymphoedema; complete treatment of deep margins; complete treatment of lateral margins; previous treatments (surgery, chemotherapy, radiotherapy, isolated limb perfusion, other treatments); number of ECT treatments (one vs. multiple); current (≤ 2 A vs. > 2 A); and electrodes (hexagonal vs. other). Multivariable analysis was performed by a logistic regression model using objective response (yes or no) and then complete response only (yes or no), using as covariates only significant variables observed in the univariable analysis. Local tumour control was expressed as local progression-free survival, which was the time from ECT to the date to relapse, progression or last follow-up (whichever came first). Overall survival was calculated from the first ECT until death or last follow-up. Survival curves were calculated by the Kaplan-Meier method. P-values < 0Á05 were considered statistically significant. One-year survival and 95% confidence intervals (CIs) were calculated using Kaplan-Meier survival analysis. Overall survival was calculated at the death (for any reason) of the patient or the last follow-up. Melanoma-specific survival was calculated at the death of the patient from melanoma disease or the last follow-up. Statistical analyses were performed with NCSS 9 software (NCSS, LLC; Kaysville, UT, U.S.A.).
Results
Patients
In total, 151 patients were treated by ECT and had data uploaded to the InspECT database by 13 European centres: Bristol (n = 4), Copenhagen (n = 14), London (n = 29), Manchester (n = 10), Middlesbrough (n = 14), Munich (n = 19), Padova (n = 7), Pavia (n = 3), Prescot (n = 9), Rome (n = 8), Turin (n = 27), Warsaw (n = 2) and Wels (n = 5). Of these patients, 37 did not have a minimum follow-up time of 60 days (a requisite to evaluate the response to treatment by the RECIST criteria). These patients were therefore excluded from the study. Reasons for exclusion were: death not directly related to treatment (n = 12; eight died due to systemic disease progression and four from other causes unrelated to melanoma or ECT treatment); use of other treatments nonspecified (n = 6); systemic disease progression (n = 6); inability to reach the hospital for follow-up visits (n = 1); and loss to follow-up (n = 12).
Therefore, of 151 patients identified from the database, 114 were evaluated for tumour response. The population and tumour characteristics of the entire cohort of 151 patients (506 treated lesions) and of the 114 patients (394 treated lesions) evaluable for response are reported in Table 1 .
Anaesthesia
Local or general anaesthesia was selected according to the tumour burden and location, as well as the patient's choice, following the standard operating procedures. General anaesthesia was used in the majority of cases (95 patients, 63%). In 36 patients ECT was performed under local anaesthesia and deep sedation (24%). The remaining 20 patients were treated with local anaesthesia alone (13%). A similar percentage distribution was observed in the group of 114 evaluable patients (62%, 26% and 12%, respectively).
Electrochemotherapy
In total, 123 patients received a single ECT session (82%), 21 patients (14%) were treated twice, five patients (3%) three times and two patients (1%) with four ECT sessions. Bleomycin was administered by systemic injection in 131 patients (87%) and by local injection in 20 patients (13%). Electrodes used were hexagonal in 383 (76%), row needle in 67 (13%) and plate in 20 (4%); multiple electrodes were used in 36 lesions (7%). Of the 506 treated target lesions, 37 (7%) were previously irradiated. Deep margins were treated by ECT in 363 lesions (72%) and lateral margins were reached in 385 lesions (76%). Similar percentage distributions were observed in the subgroup of 114 patients and 394 target lesions evaluable for response (Table 1) .
Treatment toxicity
No ECT-related serious adverse events were reported. Skin reaction (including hyperpigmentation and ulceration) after treatment was observed in 63 patients (42%), of whom in two patients it was grade 3. Fifteen patients experienced posttreatment complications: nausea (grade 1-2) in five patients (3%), flu-like symptoms (grade 1-2) in six patients (4%) and lymphoedema (grade 1-2) in four patients (3%). A similar percentage distribution was observed in the group of 114 patients: skin reaction 50% (two of grade 3), nausea 4%, flu 5% and lymphoedema 4%. Post-treatment pain was observed in 59 patients (39%). It was mild in the majority of patients and could be managed with oral analgesics. No significant changes in pain or pain medication in the course of the treatment could be observed (Table 2) .
Locoregional tumour response
Overall, 394 target lesions could be evaluated for response at > 60 days' follow-up. The median size was 9 mm [interquartile range (IQR) [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . At 60 days from ECT, 229 lesions showed complete response (58%), 77 showed partial response (20%; overall response 306 of 394 lesions, 78%), 79 lesions remained stable (20%), six had disease progression (2%) and three were not evaluable (1%) due to the presence of thick crusts. Of the 114 evaluable patients, at > 60 days' follow-up, 55 had complete response (48%), 29 had partial response (25%; overall response 84 of 114 patients, 74%), 26 patients had stable disease (23%), three had disease progression (3%) and one was not evaluable due to the presence of thick crusts. We found a significant correlation between tumour size and complete response to ECT (P < 0Á001; Table 3 ).
Predictive factors for response
Among all clinical and technical covariates included in the univariate analysis, those significantly associated with response to treatment were tumour size (< 3 cm), absence of visceral metastases, treatment of nonirradiated areas, presence of lymphoedema and coverage of deep margins and lateral margins (Table 4) .
Looking at overall response (complete response + partial response) in multivariate analysis, coverage of deep margins, absence of visceral metastases, presence of lymphoedema and treatment of nonirradiated areas were factors significantly influencing treatment efficacy. In multivariate analysis, significant factors associated with a complete response to ECT treatment were coverage of deep margins, previous irradiation of the treated area and tumour size (< 3 cm) ( Table 5) .
Local tumour control and survival
The median follow-up time was 116 days (IQR 66-201). The local tumour control survival curve is shown in Figure 1 . Twenty-seven patients were followed up for at least 200 days, and at this time the local tumour control survival rate was 86%. The 51 patients in complete response at 2 months of follow-up were locally disease-free for a median time of 125 days (IQR 70-209). Eight of them had a second ECT treatment for new lesions after a median time of 96 days (IQR 61-154). Five of these patients were treated for new lesions outside the treated area. Three patients were re-treated for recurrences in the treated area; two of them had a total of four ECT sessions and maintained local tumour control for 374 and 447 days, respectively. Overall, these eight patients experienced a median local tumour control survival of 254 days (IQR 161-389).
Among the 29 patients with a partial response, 10 were retreated by ECT after a median period of 90 days (IQR 58-131), resulting in two complete responses, four partial responses, one stable disease and one progressive disease; two patients were not evaluable. For the six patients with complete response or partial response, local control of the disease was maintained for a median follow-up time of 125 days (IQR 99-262).
Overall, 27 patients (23Á7%) were re-treated with ECT after a median follow-up time of 91 days (IQR 61-133), and in these patients local tumour control was maintained for a median of 178 days since the first ECT session (IQR 106-277). The 1-year overall survival rate in this cohort of patients was 67% (95% CI 57-77%), while melanoma-specific survival was 74% (95% CI 64-84%).
Representative clinical photographs of a patient before and after treatment are shown in Figures 2 and 3 .
Discussion
The incidence of melanoma has been rising over a number of years and it is currently the most common malignancy in young adults. Some of these patients will go on to develop metastases giving rise to pain, ulceration, malodour and bleeding. These patients have an immeasurable psychological burden and their quality of life can be adversely affected. The 5-year survival for patients with in transit disease has up to now ranged from 12% to 37%, 33 although this should improve with novel treatment regimens. 34, 35 ECT is an established therapeutic approach for the local treatment of skin metastases regardless of tumour histology. 21, 23 In a recent meta-analysis on more than 40 prospective studies comparing five skin-directed therapies (ECT, radiation, photodynamic therapy, intralesional therapy and (79) 86 (79) 42 (74) 25 (78) 38 (76) Not OR 29 (21) 23 (21) 15 (26) 7 (22) 12 (24) Complete response (CR): disappearance of the target lesion. Overall response (OR): CR + partial response (≥ 30% decrease in the diameter of the target lesion). a v 2 for trend = 20Á4 (one degree of freedom); P < 0Á001. b v 2 for trend = 0Á353 (one degree of freedom); P = 0Á55.
topical therapy), ECT demonstrated an overall response rate of 75Á4% (complete response rate 47Á5%), with a low toxicity profile (grade 3 in < 6% of patients). In this analysis, melanoma comprised 83Á3% of all cutaneous metastases. 31 Another previously published meta-analysis of ECT for cutaneous and/ or subcutaneous malignancy (including primary nonmetastatic disease) reported a complete response rate of 59%. 8 Our data retrieved from this multicentre observational prospective study, which included the largest cohort of patients treated by ECT currently reported, strongly confirm the results of previous studies, highlighting the clinical activity of ECT in terms of response rate and response duration. 13, [15] [16] [17] [18] [24] [25] [26] [27] 30, 36 Indeed, at the 2-month follow-up, a response was achieved in 78% of target lesions (58% complete response rate) and in 74% of patients (48% achieving a complete response). Notably, the local tumour control rate was 86% at 200 days of follow-up, meaning that patients with complete response maintained their response for a prolonged period of time.
These results correspond to those reported by studies analysing long-term follow-up. Carac o et al. reported that 45% of complete responders experienced a long-lasting response after one ECT session and were disease free after a mean follow-up of 27Á5 months. 18 In our study, as well as in former published studies, the clinical activity of ECT was accompanied with a favourable toxicity profile with no severe side-effects. Concerns regarding post-treatment pain have been addressed, 32, 37 with the majority of patients reported as experiencing no pain or mild pain. Patients deemed at higher risk of postprocedural pain can be identified preoperatively, and cope well with an established pain management strategy. The results from this paper showed that 39% of the patients had post-treatment pain managed by oral analgesia alone. This is similar to values previously published. 32, 37 No other severe adverse effects were noted. While the clinical indications and tolerability of ECT are widely accepted, an issue that is still controversial is the identification of patients most likely to develop and maintain response to ECT. This is particularly important as new and active systemic drugs for metastatic melanoma are available that may also be used in the same population of patients. These include both immunotherapies such as anticytotoxic T-lymphocyte-associated antigen 4 or antiprogrammed death (anti-PD)-1/anti-PD-1 ligand inhibitors, and anti-BRAF/mitogen-activated protein kinase kinase target inhibitors.
The aim of this study was to identify parameters significantly influencing treatment response and helping to decide whether a patient is more suitable for systemic therapy or ECT. To date, there is no consensus in the literature for how best to identify these factors. The only parameter that the large majority of publications agree on is the size of lesions. 38 It is well known that smaller tumours respond better, likely due to both faster healing (time to clinical response) due to a more aggressive phenotype in larger tumours, and possibly also to technical limitations when treating very large tumours.
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We found a significant and inverse trend between tumour size and treatment response. Treatment efficiency decreased with increasing size of tumour nodules (Table 3) . However, only a few studies have tried to identify other factors influencing treatment response. Solari et al. found that response rate significantly correlated in univariate analysis with both the number (fewer than 10 or more than 10) and the size (< 2 cm or > 2 cm) of metastases, while in multivariate analysis only the tumour size maintained a statistically significant correlation in 39 patients. 27 However, this study was conducted on a relatively small cohort including not only melanoma but also other tumours. Campana et al. studied 85 patients with metastatic melanoma and found that tumour size and number of lesions were significant predictive factors for response in multivariate analysis. 17 Increasing numbers of electrode applications and ECT cycles were reported as predictors of local tumour control, and location of nodules on the lower limb was associated with improved survival. 17 In the present study, we identified the following predictors of response: coverage of deep tumour margins, absence of visceral metastases, presence of lymphoedema and treatment of nonirradiated areas. Our analysis identified factors not previously reported in patients with melanoma. The size of the lesion (< 3 cm in diameter), which is a well-known prognostic parameter in ECT-treated patients, was singled out by the multivariate model only in relation to a significantly higher probability of achieving a complete response to treatment. This factor was not associated with a better overall response. On the other hand, complete coverage of deep margins and treatment of tumours in nonirradiated areas were significant parameters on multivariate analysis for overall and complete response. The relevance of completely targeting the deep margins could imply that patients with deep and/or subcutaneous metastases could have a lower response rate to ECT than patients with superficial skin lesions, although the assessment of deep margins still needs to be assessed in a more reproducible way. The number of tumours was not found to be a predictor of locoregional tumour response in our patients.
The biological background leading to reduced ECT activity in the presence of these parameters can be hypothesized even if it is not specifically addressed in this paper. The presence of visceral metastases could be considered as a putative biomarker of rapid cell growth and therefore aggressive metastatic behaviour. In these cases, one could infer that the local approach by ECT alone would be inadequate to manage local disease occurrence or the onset of new skin lesions. In addition, there is a higher tumour load in patients with systemic metastases, and a retrograde metastasis from viscera to the skin is possible. This could occur if lymph node metastasis results in a blockage of lymph flow, ineffective lymphatic valves, and subsequent retrograde lymphatic flow. Intriguingly, the presence of lymphoedema was associated with a higher response to ECT. Lymphoedema is a common surgical side-effect of radical node dissection, and therefore patients with skin 'in transit metastases' often present with this picture. Data are emerging that ECT may be an efficient way of presenting intact antigens to the immune system, as electroporation is essentially a nonthermal therapy. 39 Case reports of excellent responses after sequential ECT and immunotherapy are accumulating, and a study has found homing of T lymphocytes to tumour lesions after ECT of other lesions, in combination with local interleukin-2. 34 What can be speculated, but must be further investigated, is that an increased presence of lymphocytes in the treated area may have a positive effect on response. Such a response may not be seen in isolated limb perfusion, for example, because the drugs used will also be cytotoxic to lymphocytes. Radiotherapy is not a standard treatment for primary melanoma, but can be used to treat metastatic lesions. The observation of better ECT response in nonirradiated lesions (when compared with lesions in patients with previous irradiation) could be explained by reduced clinical tumour activity due to modification in the tumour microenvironment and vascularization induced by radiotherapy. Fibrosis is a late side-effect of radiation caused by premature senescence and accelerated postmitotic differentiation, leading to excessive collagen production by irradiated mesenchymal cells (fibroblasts, myofibroblasts and smooth muscle cells), and not by cell death. 40, 41 The presence of fibrosis may alter the electric potential delivered during ECT treatment. Conversely there is laboratory evidence that ECT performed before radiotherapy 42 or in combination with irradiation 43 might give rise to good antitumour results. It is thought that the antitumour effectiveness of ECT is increased by radiation in the laboratory model. Other studies have shown that ECT acts synergistically with radiotherapy, with enhanced tumour toxicity. [42] [43] [44] Possibly, in melanoma, restricted blood flow and fibrosis may also lead to decreased immunological activity in the area.
It is important to determine the various factors that will positively affect the outcome of patients with melanoma treated with ECT. Our data suggest that patients with skin metastases could be selected for ECT treatment if the disease was superficial, in the presence of lymphoedema, in the absence of visceral metastases or previous irradiation, and if the tumour nodules were < 3 cm in size. It may even be possible that ECT could favourably influence immunotherapeutic approaches, and studies are ongoing to investigate this. Patients with visceral metastases, absence of lymphoedema, larger and deep skin metastases and with previous radiotherapy could be treated earlier with a systemic approach and ECT performed only if needed to control bleeding of metastases.
There are a number of limitations to the current study. Patient review is not standardized in all of the centres involved in the data collection. In some units, ECT is carried out by specific personnel and therefore assessment of response is likely to be biased. The number of patients assessed for the cohort study does not accurately represent the total number of patients with melanoma treated. The various centres joined InspECT at different times and the ability to upload data was related to local resources and the availability of personnel. The ability to determine whether or not the deep margin of a tumour is treated remains subjective, by the treating clinician. One way to characterize the deep treatment margins objectively would be by intraoperative imaging by ultrasound.
Future studies on ECT could explore the use of ECT as monotherapy for localized skin metastases, only adding systemic treatments when there is systemic progression to prevent early resistance to systemic treatments and to achieve long-lasting survival rates. It is already well established that ECT does not influence the metastatic potential of tumour cells. 45 If it is not possible to treat deep tumour margins it may be necessary to add a systemic treatment early due to worse response rates (10Á3% for complete response and 28Á5% for overall response).
ECT is a once-only treatment, and can be quickly performed even before or between other treatments. Clear indications include bleeding, 10, 19 which is a frequent problem for patients with metastatic melanoma. Local responses, which are to a high degree achievable with ECT, may alleviate the patient from local tumour burden and progression. The collection of InspECT data began before the introduction of targeted therapies, such as those aimed at BRAF, c-kit, MAP2K1 and NRAS mutations, and so their status has not been systematically evaluated in our patients. Future studies could ascertain whether ECT activity could be influenced by the mutation status or is independent from it. Ultimately a randomized controlled trial will be required to determine whether there is a difference in locoregional response rate and overall survival when ECT is compared with other well-established treatment modalities. Future studies to explore the combination of ECT with systemic treatments will become necessary with time as more of our patients become eligible for treatment with new agents. 30 The combination of ECT with immunotherapy or targeted therapies could be a strategy to target both local and distant unreachable or untreated lesions. 25 
